Pentraxins are a family of ancient innate immune mediators conserved throughout evolution. The classical pentraxins include serum amyloid P component (SAP) and C-reactive protein, which are two of the acute-phase proteins synthesized in response to infection 1,2 . Both recognize microbial pathogens and activate the classical complement pathway through C1q (refs 3 and 4). More recently, members of the pentraxin family were found to interact with cell-surface Fcc receptors (FccR) and activate leukocytemediated phagocytosis 5-8 . Here we describe the structural mechanism for pentraxin's binding to FccR and its functional activation of FccR-mediated phagocytosis and cytokine secretion. The complex structure between human SAP and FccRIIa reveals a diagonally bound receptor on each SAP pentamer with both D1 and D2 domains of the receptor contacting the ridge helices from two SAP subunits. The 1:1 stoichiometry between SAP and FccRIIa infers the requirement for multivalent pathogen binding for receptor aggregation. Mutational and binding studies show that pentraxins are diverse in their binding specificity for FccR isoforms but conserved in their recognition structure. The shared binding site for SAP and IgG results in competition for FccR binding and the inhibition of immune-complex-mediated phagocytosis by soluble pentraxins. These results establish antibody-like functions for pentraxins in the FccR pathway, suggest an evolutionary overlap between the innate and adaptive immune systems, and have new therapeutic implications for autoimmune diseases.
Pentraxins are a family of ancient innate immune mediators conserved throughout evolution. The classical pentraxins include serum amyloid P component (SAP) and C-reactive protein, which are two of the acute-phase proteins synthesized in response to infection 1, 2 . Both recognize microbial pathogens and activate the classical complement pathway through C1q (refs 3 and 4) . More recently, members of the pentraxin family were found to interact with cell-surface Fcc receptors (FccR) and activate leukocytemediated phagocytosis [5] [6] [7] [8] . Here we describe the structural mechanism for pentraxin's binding to FccR and its functional activation of FccR-mediated phagocytosis and cytokine secretion. The complex structure between human SAP and FccRIIa reveals a diagonally bound receptor on each SAP pentamer with both D1 and D2 domains of the receptor contacting the ridge helices from two SAP subunits. The 1:1 stoichiometry between SAP and FccRIIa infers the requirement for multivalent pathogen binding for receptor aggregation. Mutational and binding studies show that pentraxins are diverse in their binding specificity for FccR isoforms but conserved in their recognition structure. The shared binding site for SAP and IgG results in competition for FccR binding and the inhibition of immune-complex-mediated phagocytosis by soluble pentraxins. These results establish antibody-like functions for pentraxins in the FccR pathway, suggest an evolutionary overlap between the innate and adaptive immune systems, and have new therapeutic implications for autoimmune diseases.
The pentraxin family is divided into two subclasses, the classical short-chain pentraxins, C-reactive protein (CRP) and SAP, and the long-chain pentraxins 3 . Both SAP and CRP recognize various pathogenic bacteria, fungi and yeasts 3 , and activate the classical complement pathway through C1q (ref. 4 ). Long-chain pentraxins such as PTX3, which contain an additional amino-terminal domain, are produced by macrophages and myeloid dendritic cells in response to proinflammatory stimuli 9, 10 . Humans have three classes of activating Fcc receptors-FccRI, FccRIIa and FccRIII-and one inhibitory receptor, FccRIIb 11 . In addition to activating phagocytosis through FccR [5] [6] [7] [8] , both SAP and CRP also induce protective immune responses 12 , and high levels of CRP protect mice from endotoxin shock through FccR 13, 14 . Although pentraxins can both activate and regulate immune responses, the molecular mechanisms and the balance of these antibody-like functions remain unresolved. Here we present structural and functional evidence for the involvement of pentraxins in the activation of FccR and suggest their potential role in modulating antibody-mediated inflammatory responses.
Although immune complexes are known to activate FccR, leading to phagocytosis and cytokine secretion, it is not clear whether pentraxins induce similar FccR activation 7, 8 . To investigate whether FccR recognize pathogens through pentraxin opsonization, we examined the engulfment of pentraxin-opsonized zymosan by human monocyte-derived macrophages (MDMs). Zymosan particles labelled with Texas red were efficiently internalized by MDMs on opsonization with human SAP, CRP or IgG in comparison with unopsonized particles (Fig. 1a ). The cup-shaped enrichment of FccRIIa (labelled green) surrounding the zymosan particles bound to SAP and CRP indicates the involvement of FccR in phagocytosis. The addition of soluble IgG decreased the phagocytosis of SAP-opsonized zymosan by 90% from 3.8 6 0.5 to 0.4 6 0.2 (means 6 s.e.m.) zymosan particles per MDM, further confirming the role of FccR. We then investigated cytokine secretion as a result of SAP-FccR interaction. To avoid activation mediated by zymosan and endotoxin, CD14 1 monocytes were treated with purified SAP in either an aggregated or monomeric form without zymosan and in the presence of polymixin B. Treatment with SAP resulted in dose-dependent secretion of interleukin (IL)-10, IL-8 and IL-6 by monocytes ( Fig. 1b) , and only the aggregated SAP, not the monomeric SAP, stimulated cytokines, suggesting a requirement for receptor crosslinking by SAP in cytokine production ( Fig. 1c ). Cytokine secretion was markedly decreased if SAP was pretreated with bead-bound proteinase K or precleared with phosphoethanolamine (PE)-conjugated Sepharose (Fig. 1d ). In addition, antibodies against FccR as well as a Syk inhibitor, piceatannol, which blocks FccR signalling, significantly inhibited cytokine secretion, confirming the involvement of FccR (Fig. 1e , f). To assess the contribution of potential contaminating lipopolysaccharide and/or peptidoglycan in the SAP sample to cytokine secretion, bonemarrow-derived macrophages (BMDMs) from Myd88 2/2 and RIP2 2/2 mice were treated with SAP and assayed for cytokine production. Similar or higher levels of IL-6 and CCL2 were detected in SAPtreated but not PBS-treated BMDMs from Myd88 2/2 mice compared with wild-type BMDMs (Fig. 1g ). Tumour necrosis factor (TNF)-a production was lower in SAP-treated Myd88 2/2 BMDMs than in wild-type BMDMs but remained 10-20-fold higher than after treatment with PBS. Similarly, comparable amounts of cytokines were released in BMDMs from the RIP2 2/2 and wild-type mice in response to SAP. The results show that BMDMs from both Myd88 2/2 and RIP2 2/2 mice produce cytokines on stimulation with SAP, independently of Toll-like receptor (TLR) and nucleotide-binding oligomerization domain-like (NOD) receptor pathways. However, a partial decrease in TNF-a level from the Myd88 2/2 compared with the wild-type mice indicates a potential synergistic activation between FccR and TLR.
To investigate the structural mechanism for pentraxin-mediated FccR activation, we determined the crystal structure of human SAP in complex with the extracellular domain of FccRIIa to 2.8 Å resolution, with final R-factors of 20.7% and 27.9% for R cryst and R free , respectively (Supplementary Table 1 ). The refined (2F o 2 F c ) density map was continuous throughout the complex except for one SAP loop, residues 140-146, that was disordered in four of the five SAP subunits. Each asymmetric unit contained one FccRIIa molecule bound to the effector face of one SAP pentamer with the D1 and D2 domains of the receptor spanning diagonally over SAP and contacting the A and C subunits of the pentraxin, respectively (Fig. 2 ). This diagonal spanning of FccRIIa over the SAP pentamer ensures a 1:1 stoichiometry in SAP-FccRIIa recognition, thus setting the need for the binding of multivalent pathogens in Fc receptor aggregation. The conformations of the receptor-contacting subunits A and C of SAP do not differ significantly from the other three non-receptor contacting subunits nor from those of receptor-free SAP 15 (Fig. 2d ). In fact, the entire SAP pentamer of the current complex, despite the lack of bound Ca 21 ions and small ligands, can be superimposed on that of receptor-free, Ca 21 -bound SAP with a root mean squared (r.m.s.) deviation of 0.8 Å . Similarly, the structure of FccRIIa in the complex is nearly identical to that of ligand-free FccRIIa, with r.m.s. differences of 0.9 Å for 171 Ca atoms 16 , suggesting rigid body docking between SAP and the receptor. The only conformational change in the receptor involved a movement of roughly 3 Å in the N-terminal BC loop (residues 28-35) of the FccRIIa towards the A subunit of SAP (Fig. 2d) .
The complex buries a total of about 1,962 Å 2 of solvent-accessible surface area, equally distributed between the A and C subunits of SAP, and has a shape complementarity index (S c ) of 0.58 (ref. 17) , similar to those between the T-cell antigen receptor (TCR) and the major histocompatibility complex, between KIR and HLA (S c 5 0.5-0.6) but less than those between antibodies and antigens (S c . 0.7) 18, 19 . Both the A and C subunits of SAP use their ridge helices (Pro 166 to Gln 174), especially Tyr 173 and Gln 174, and the carboxy-terminal residues (Pro 200 to Pro 204) to contact the D1 and D2 domains of FccR ( Fig. 3) , thus highlighting these residues as functional hotspots on SAP. On the receptor side, both the D1 and D2 domains use their topological equivalent BC, C9E loops and the C strand to contact SAP, and the binding site is away from the predicted N-linked glycosylation sites. The D1-A interface consists of a salt bridge between Asp 35 of FccRIIa and Arg 38 of SAP, four hydrogen bonds, and van der Waals interactions involving Tyr 173 and Gln 174 from the ridge helix of SAP ( Fig. 3a and Supplementary Table 2 ). The D2-C interface, in contrast, is entirely mediated by van der Waals interactions ( Fig. 3b and Supplementary Table 2 ). Residues at the D1-A interface are more Anti conserved across the species than those at the D2-C interface ( Supplementary Fig. 1 ).
The critical receptor contact region of SAP involves the ridge helix and its pentameric assembly, which are conserved features of the pentraxin family. Similarly, the structure of FccRIIa showing only 1.2 Å r.m.s. deviation between the Ca atoms from FccRIII is well conserved; significant interface sequence homology is shared between FccRs ( Supplementary Fig. 1 ). This suggests the possibility of a broader recognition between pentraxins and FccR 5, 7, 8 . Using BIAcore binding, we showed that SAP, CRP and PTX3 all recognized FccRs with affinities ranging from 10 to 0.1 mM, similar to those between isoforms of IgG and FccR 20 ( Supplementary Table 3 and Supplementary Fig. 2 ). SAP bound most tightly to FccRI, with a dissociation constant (K d ) of 0.48 mM, and more weakly to FccRIIa, FccRIIb and FccRIII (K d 1-3 mM). CRP had similar affinities (2-4 mM) for all four FccR isoforms. PTX3 recognized only FccRIII. SAP and CRP, but not PTX3, recognized the inhibitory Fc receptor, FccRIIb, suggesting a potential regulatory function for these pentraxins.
The structural conservation and broad pentraxin-FccR recognition suggest that the complex structure is a prototypic model for pentraxin recognition by FccR. To test this, we modelled the CRP structure into the current SAP-FccRIIa complex. Although SAP and CRP differ in their relative monomer orientations with respect to the pentamer by about 25u (refs 21, 22) , they use common residues at the pentameric interface, and CRP can be placed at the FccRIIa interface in the model without serious steric hindrance ( Supplementary Fig.  3 ). To verify the CRP-FccRIIa model, three putative interface residues of CRP, including the salt-bridge-forming residue His 38 and two ridge-helix residues, Tyr 175 and Leu 176, were mutated and the binding of mutant CRP to FccR was measured by BIAcore. Whereas wild-type CRP binds FccRIIa with 1.9 mM affinity, H38A, Y175L and L176A mutations resulted in a 2-8-fold decrease in the binding affinity in solution ( Supplementary Table 3 ). These mutational results, together with the earlier mutagenesis studies 23 , indicate that FccR recognition is conserved between SAP and CRP. A similar decrease in affinity was also observed between the CRP mutants and FccRIII, indicating a further structural preservation in FccRIII recognition. The mutations did not affect the recognition of FccRI by CRP, indicating a variation in CRP-FccRI interaction potentially attributed to the presence of an additional domain in FccRI.
Polymorphism at residue 131 of FccRIIa affects its recognition of immunoglobulins [24] [25] [26] . This polymorphism also affected CRP binding 27 . By isothermal titration calorimetry, CRP bound the arginine and histidine isoforms of FccRIIa with about 4 mM and less than 10 mM affinities, respectively ( Supplementary Fig. 4 ). The side chain of Arg but not His 131 could form hydrogen bonds with the main chains of Gly 178 and Pro 179 from CRP.
Because FccRIIa recognized both SAP and IgG, we then examined whether the receptor's binding to SAP affected its binding to immunoglobulins. Unexpectedly, the overlay of the SAP-FccRIIa structure on the Fc-FccRIII structure showed that the IgG binding site on the Fc receptor partly overlapped with that for SAP 28 (Fig. 4) . Both SAP and IgG interact with the BC and FG loops as well as the C and C9 strands of the FccR D2 domain, creating a steric clash between the C H 2 domain of IgG and the C and D subunits of SAP. The shared recognition predicts competition between IgG and SAP for FccR binding. Indeed, with a BIAcore binding assay, the association between SAP and FccRIIa was effectively competed off by increasing concentrations of IgG1 (Fig. 4c ). Furthermore, soluble SAP blocks, in a dose-dependent manner, the phagocytosis of IgG-opsonized sheep red blood cells (EIg) by human MDMs (Fig. 4d) . Similarly, binding of CRP to Fc receptors (FccRIIa, FccRIIb and FccRIII) was also inhibited by IgG1 in a dose-dependent manner (Fig. 4e) , and CRP inhibited the IgG-mediated phagocytosis of EIg (Fig. 4f) . The similarity between CRP and SAP in competing with the binding of IgG to FccR further supports their conserved receptor recognition structure. As the plasma concentration of CRP but not SAP may reach more than 200 mg ml 21 during the acute phase 2 , the inhibition of IgG-mediated phagocytosis by CRP suggests a potential downregulation of antibody-mediated FccR activation by CRP in the late stage of the acute phase, when an excess amount of soluble CRP is available.
Thus we have shown, through structural and functional studies, that pentraxins directly recognize FccR, activate phagocytosis and induce cytokine secretion. Although pentraxins recognized FccR with variable affinity and specificity, they probably share a conserved receptor recognition. The overlapping SAP-binding and IgG-binding sites on FccR blocked antibody-mediated phagocytosis by soluble pentraxins. Taken together, these results provide structural and functional evidence for the involvement of pentraxins in FccR-mediated immune functions. Thus, pentraxins possess similar functions to those of antibodies that activate both the complement and Fc receptor pathways. This parallel between pentraxins and antibodies suggests that pentraxins were ancient antibodies in evolution, and that they function as antibodies in more primitive organisms. The competition in FccR binding between IgG and pentraxins suggests potential novel strategies for treating autoimmune diseases on the basis of soluble pentraxins rather than intravenous immunoglobulin.
METHODS SUMMARY
Recombinant ectodomains of FccRIIa and IIb1 (residues 1-171) were expressed in Escherichia coli and refolded by using a pET30a vector with a C-terminal His 6 tag. SAP and CRP were purified from human plasma or pleural fluid. CRP mutants were expressed in baculovirus system. For confocal and fluorescence microscopy, human MDMs were incubated with SAP, CRP, rabbit anti-zymosan IgG or PBS-opsonized zymosan (conjugated with Texas red) at 37 uC for 30 min. The samples were stained with an anti-CD32 monoclonal antibody and an Alexafluor 488-conjugated goat anti-mouse F(ab9) 2 . For inhibition, soluble IgG was added during the phagocytosis. For phagocytosis of sheep red blood cells (sRBCs or E), fresh sRBCs were opsonized with a rabbit anti-sRBC IgG and mixed with MDMs by centrifugation at a ratio of 20:1 and incubation at 37 uC for 2 h in the presence or absence of SAP, CRP, anti-CD32 or anti-CD64. For cytokine release experiments, purified CD14 1 monocytes were incubated with 50 mg ml 21 (or otherwise indicated) concentrations of aggregated SAP ( Supplementary Fig. 5 ) for 24 h, and cytokines were measured by ELISA. Monomeric SAP was isolated on a Superdex 200 column in the presence of 10 mM methyl-b-D-galactopyranoside. SAP was degraded by a bead-bound proteinase K or depleted by PE-conjugated Sepharose. Anti-FccR blocking antibodies or isotype controls were added at 5 mg ml 21 before the addition of SAP. Bone marrow cells from Myd88 2/2 , RIP2 2/2 and wild-type mice were differentiated to BMDMs and then incubated with 50 mg ml 21 aggregated SAP for cytokine release. The complex crystals were grown from 2.0 M (NH 4 ) 2 SO 4 , 5% isopropanol by hanging-drop vapour diffusion; X-ray data were collected to 2.8 Å resolution at SER-CAT beamlines and processed with HKL2000. The complex structure was solved by a molecular replacement method with the Phenix package. Model building and refinement were performed with O and CNS.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
METHODS
Confocal and fluorescence microscopy. Human MDMs were differentiated on glass coverslips in 24-well plates as described previously 29 . Opsonized zymosan was prepared by incubating Texas red-conjugated zymosan (Molecular Probes) for 30 min at 37 uC with CRP or SAP at 100 mg ml 21 in HBSS (with Ca 21 and Mg 21 ) or rabbit anti-zymosan IgG (Molecular Probes), and added to cells at a final concentration of 10 6 particles per well and incubated for 30 min at 37 uC in X-vivo medium. Coverslips were fixed with 2% paraformaldehyde, permeabilized with 0.25% Triton X-100 in PBS, and stained with 5 mg ml 21 IV.3 monoclonal antibody and Alexafluor 488-conjugated goat anti-mouse F(ab9) 2 (Caltag). Confocal images of optical sections 1 mm thick were collected with a Zeiss LSM 510 META system. For inhibition of phagocytosis through FccR, soluble IgG (10 mg ml 21 intravenous immunoglobulin; Baxter) was added for 60 min before the addition of opsonized zymosan, and random field images were collected with a Zeiss Axioskop 2 plus fluorescent microscope. Cytokine release experiments. CD14 1 monocytes were purified from peripheral blood mononuclear cells by using CD14 MACS beads and LS columns (Miltenyi), incubated with 50 mg ml 21 or otherwise indicated concentrations of purified SAP ( Supplementary Fig. 5 ) for 24 h in 96-well plates at a concentration of 5 3 10 5 cells per well in 200 ml of complete RPMI medium (containing 10% FBS, 50 mg ml 21 gentamicin and 10 mg ml 21 polymixin B). Cytokine levels were measured by ELISA with BD BioSciences reagents 30 . Aggregated SAP (200-500 kDa) was prepared by the removal of serum during purification. Addition of 0.5 M salt reverted the aggregates to pentameric SAP, which was dissociated into monomers by the addition of 100 mM methyl-b-D-galactopyranoside (Sigma-Aldrich) and isolated on a Superdex 200 column in 10 mM HEPES, pH 7.4, 0.15 M NaCl, 10 mM methyl-b-D-galactopyranoside, 2 mM CaCl 2 . The endotoxin level of purified SAP was estimated by the Limulus assay (Lonza) as 83 pg ml 21 . To remove SAP proteolytically, 100 ml of 1 mg ml 21 SAP was incubated for 30 min at 40 uC with 0.2 mg of bead-bound proteinase K (Sigma). The digested material was filtered and added to cells with an amount of SAP equivalent to 50 mg ml 21 . SAP was also removed by incubation with 50 ml of PEconjugated Sepharose in the presence of 2 mM calcium. Piceatannol was added to monocytes at 25 mg ml 21 , with 2.5% ethanol as the vehicle control, for 30 min at 37 uC before the addition of SAP. For antibody-blocking experiments, cells were pretreated for 30 min with 5 mg ml 21 monoclonal antibody specific for FccR or isotype controls before adding SAP. Antibodies were purchased as follows: anti-human CD64 (clone 10.1), mouse IgG1 (Ancell), anti-human CD32 (clone FLI8.26) and mouse IgG2b (BD Biosciences), and anti-human CD16 (clone 3G8; Medarex). Anti-human CD32 (clone IV.3) was purified from a hybridoma cell line (ATCC). Bone marrow cells from wild-type C57BL/6 and two 3-month-old MyD88-knockout mice were plated, and adherent cells were differentiated for 6 days in DMEM medium containing 20% FBS, 30% L-cell supernatant, 25 mM HEPES and 5 mg ml 21 streptomycin and penicillin. Bone marrow cells from two 3-month-old RIP2-deficient mice and control, ten-timesbackcrossed, C57BL/6N mice were differentiated similarly. BMDMs were incubated for 24 h with 50 mg ml 21 aggregated SAP in 10% FBS containing DMEM in the absence of polymixin B and assayed for cytokine release as described above, with mouse cytokine ELISA kits (R&D Systems). Results are means 6 s.e.m. for triplicate wells in two or three experiments. Significance levels: asterisk, P , 0.05; two asterisks, P , 0.01; three asterisks, P , 0.001. Purification, crystallization and structural determination. Recombinant ectodomains of FccRIIa and IIb1 (1-171) were expressed in E.coli and refolded using a pET30a vector with a C-terminal His 6 -tag 31 . SAP and CRP were purified from human plasma or pleural fluid as described ( Supplementary Fig. 5) 8, 32 . Mutant CRP proteins were expressed in the baculovirus system as previously described 23 . For crystallization of the complex, SAP pentamer was first dissociated into monomers by urea-chelation 33 . After dialysis to remove urea, SAP was mixed with FccRIIa in a 1:1 (monomeric SAP to FccRIIa) molar ratio in 10 mM HEPES, pH 7.4, 0.05 M NaCl, and 0.01% NaN 3 , and concentrated to a final OD 280 of 12. The complex crystals were grown from 2.0 M (NH 4 ) 2 SO 4 , 5% isopropanol by hanging drop vapour diffusion. The X-ray data were collected to 2.8 Å resolution at SER-CAT beamlines using flash cooled crystals and processed with HKL2000 (ref. 34) (Supplementary Table 1 ). The structure of the SAP-FccRIIa complex was solved by a molecular replacement method with the program Phaser 35 from the Phenix package 36 using either the poly-alanine SAP subunit (1SAC) or CRP (1GNH) subunit and FccRIIa (1H9V) as search models. Model building and refinement were carried out using O 37 and CNS 38 . Hinge angles were calculated using HINGE 39 . Docking of CRP to SAP-FccRIIa complex was done using Hex 5.0 with standard parameters 40 . All structure figures were generated with Pymol 41 . Phagocytosis of sRBC. Human monocytes (2.5 3 10 5 ) were differentiated into MDMs for 6 days in RPMI-1640 medium supplemented with 10 ng ml 21 granulocyte-macrophage colony-stimulating factor, 10% FBS, 20 mM glutamine, and penicillin and streptomycin. Fresh sRBCs were opsonized with a rabbit anti-sRBC IgG (1:48,000 dilution; Cappel) in PBS for 1 h at 4 uC. Phagocytosis was initiated by centrifuging IgG-opsonized sRBCs onto MDMs at a ratio of 20:1 and incubating them at 37 uC for 2 h, and was terminated by lysis of the non-ingested sRBCs twice in water for 30 s. SAP, CRP, anti-CD32 or anti-CD64 was added for 30 min before the addition of opsonized sRBCs. The phagocytic index (per cent) was quantified by counting the total number of internalized sRBCs as a proportion of the total number of MDMs in eight random fields (about 200 cells per field) with an Olympus IX70 microscope. The results represent at least three independent experiments with more than 1,000 cells counted per experiment and are presented as means 6 s.d. Significance levels: asterisk, P , 0.05; two asterisks, P , 0.01; three asterisks, P , 0.001.
